Call 888-776-0942 from 8 a.m. to 10 p.m. Eastern Time

Mountain View, California, September 1, 2021/PRNewswire/ - AliveCor, a leading innovator in FDA-approved personal electrocardiogram (ECG) technology and services, announced today that it has discovered that KardiaMobile® 6L devices are superior to single-lead devices according to The results of the largest study evaluating the reliability of commercially available personal electrocardiogram devices for detecting atrial fibrillation (AF), and the first study ever to compare multiple personal electrocardiogram devices. The poster titled "Comparison of over-the-counter smart watches and devices for detecting atrial fibrillation based on ECG" was presented at the ESC Conference 2021.1

In this study, the researchers used a single-center, prospective, non-randomized, and referee-blind study to compare three personal ECG devices in 220 continuous electrical cardioversion (ECV) AF patients. The reliability of tremor. The author collected standard 12-lead ECG records immediately before ECV, and then collected four 30-second ECG records from three different devices (including Withings® Move ECG, Apple Watch® Series 5 and KardiaMobile 6L). The standard 12L-ECG is interpreted by a cardiologist. The sensitivity and specificity of each AF detection algorithm were determined, as well as the interpretation of the data from each device by the cardiologist.

"We are very pleased to see that our KardiaMobile 6L device outperforms other commercial personal electrocardiograms in this pioneering study," said Dr. Dave Albert, Chief Medical Officer and Founder of AliveCor. "We continue to advance our technology and strive to further optimize the peculiarities of our KardiaMobile technology."

The results show that the sensitivity/specificity of the AF algorithm used on all three devices (Withings 98%/95%, Apple® 94%/98%, Kardia 99%/91%. All P>0.05) are generally similar, but The KardiaMobile 6L device is the most sensitive test, with the highest percentage of suspected AF (57%). The proportion of unexplainable ECGs shared by all devices in the study was similar (all P>0.05). Although the watch is removed from the wrist and the lead II except the I lead is recorded, the cardiologist’s interpretation of KardiaMobile 6L is the best, its sensitivity to atrial fibrillation is 99%/97%, and it is detecting The accuracy of atrial flutter is doubled (63% compared with 28% and 33% for Withings and Apple Watch, respectively). The authors concluded that "Kardia 6L (yes) is better than single-lead devices."

About KardiaMobile 6L KardiaMobile 6L is the first and only six-lead personal electrocardiogram approved by the FDA. It detects more arrhythmias than any other personal ECG device. KardiaMobile 6L can instantly detect atrial fibrillation, bradycardia, tachycardia, sinus rhythm with supraventricular ectopic, sinus rhythm with ventricular premature beats, sinus rhythm with wide QRS and normal in the ECG Heart rhythm. Cardiologists can also use the readings of KardiaMobile 6L to measure the QT interval, which is an important risk factor for many drugs and congenital problems.

About AliveCor AliveCor, Inc. is using deep learning to transform heart care. The FDA-approved KardiaMobile device is the world's most clinically proven personal electrocardiogram solution. KardiaMobile 6L can instantly detect atrial fibrillation, bradycardia, tachycardia, sinus rhythm with supraventricular ectopic, sinus rhythm with ventricular premature beats, sinus rhythm with wide QRS and normal in the ECG Heart rhythm. Kardia is the first AI-enabled platform to help patients and clinicians detect atrial fibrillation early, which is the most common arrhythmia and is associated with a high risk of stroke. AliveCor's enterprise platform allows third-party vendors to easily and profitably manage the heart conditions of patients and customers using state-of-the-art tools that provide simple front-end and back-end integration for AliveCor technology. AliveCor protects its customers through strict data security and compliance practices, achieving HIPAA compliance and SOC2 Type 1 and Type 2 certification. AliveCor is a privately held company headquartered in Mountain View, California. A "consumer" or "personal" ECG is an ECG device that can be sold directly to consumers. For more information, please visit alivecor.com.

Apple and Apple Watch® are trademarks of Apple Inc. registered in the United States and other countries and regions. Withings is a registered trademark of Withings.

1 Abstract Title: Comparison of over-the-counter smart watches and devices based on ECG to detect atrial fibrillation

More news releases on similar topics

Cision Distribution 888-776-0942 8 a.m. to 9 p.m. Eastern Time